AEON Biopharma (NASDAQ:AEON) Receives Buy Rating from HC Wainwright

AEON Biopharma (NASDAQ:AEON)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $18.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 175.23% from the company’s current price. HC Wainwright also issued estimates for AEON Biopharma’s Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.32) EPS and Q4 2025 earnings at ($0.24) EPS.

AEON Biopharma Trading Down 3.7 %

Shares of AEON Biopharma stock opened at $6.54 on Wednesday. AEON Biopharma has a 52-week low of $3.37 and a 52-week high of $17.17. The stock has a 50-day simple moving average of $10.64 and a 200-day simple moving average of $7.78.

AEON Biopharma (NASDAQ:AEON) last announced its quarterly earnings results on Friday, March 29th. The company reported ($0.71) earnings per share (EPS) for the quarter. Equities research analysts expect that AEON Biopharma will post -1.54 EPS for the current fiscal year.

Institutional Investors Weigh In On AEON Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in AEON. Northern Trust Corp lifted its holdings in AEON Biopharma by 53.4% in the 4th quarter. Northern Trust Corp now owns 49,819 shares of the company’s stock worth $359,000 after purchasing an additional 17,341 shares during the last quarter. Formidable Asset Management LLC acquired a new stake in AEON Biopharma in the 3rd quarter worth approximately $360,000. Vanguard Group Inc. acquired a new stake in AEON Biopharma in the 3rd quarter worth approximately $1,085,000. Finally, Atalaya Capital Management LP acquired a new stake in AEON Biopharma in the 3rd quarter worth approximately $19,827,000. 22.78% of the stock is currently owned by institutional investors and hedge funds.

AEON Biopharma Company Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.